// App-Quantinova.ai

1006 : The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.

Researchers

Presenter

  • Leisha A. Emens

Principal Investigators

  • Leonard D Goldstein

  • Peter Schmid

  • Hope S. Rugo

  • Sylvia Adams

  • Carlos H. Barrios

  • Andreas Schneeweiss

  • Veronique Dieras

  • Hiroji Iwata

  • Ching-Wei Chang

  • Hartmut Koeppen

  • Stephen Y. Chui

  • Sherene Loi

  • Luciana Molinero

Medical Centers

  • University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, Genentech, Inc, South San Francisco, CA

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • University of California, San Francisco, San Francisco, CA

  • New York University Cancer Institute, New York, NY, Hospital São Lucas, PUCRS, Porto Alegre, Brazil

  • University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany

  • Dept. of Radiation Oncology, Centre Eugene Marquis, Rennes, France

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Genentech, Inc., South San Francisico, CA

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

Locations

  • United Kingdom

  • Brazil

  • Germany

  • France

  • Japan

  • Australia

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • Atezolizumab

  • Paclitaxel

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02425891

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved